Exposure to high-frequency electromagnetic fields at work not associated with brain tumours
02 August 2018
No clear associations have been found between occupational exposure to high frequency electromagnetic fields (EMF) and risk of glioma or meningioma, in one of the largest epidemiological studies performed to date and led by Barcelona institute for Global Health (ISGlobal), an institution supported by "la Caixa" Foundation.
However, the findings highlight the need for further research on radiofrequency magnetic fields and tumour promotion, as well as possible interactions with other frequencies and with chemicals.
High frequency electromagnetic fields are a form of non-ionising radiation and comprise intermediate frequency (3kHz-10MHz) and radiofrequency (10MHz-300 GHz). Based on limited animal and epidemiological evidence, they were declared by WHO's International Agency for Research on Cancer (IARC) in 2011 as possibly carcinogenic to humans, but few recent studies have provided further evidence regarding exposure at work. "This is the largest study of brain tumours and occupational high-frequency EMF exposure to date", explains senior author Elisabeth Cardis, Head of the Radiation Programme at ISGlobal.
The researchers developed a 'source-exposure matrix' based on measurements collected from the literature for EMF sources reported by the study participants. With this tool plus detailed individual data, they estimated individual RF and IF exposure at work and analysed the possible association with risk of glioma or meningioma, two of the most frequent brain tumours in adults. The INTEROCC study, performed under the umbrella of INTERPHONE, and supported by the European project GERoNiMO, comprised 2,054 glioma cases, 1,924 meningioma cases and 5,601 controls from seven countries. Occupational sectors that involved exposure to electromagnetic fields included working with or near radars, telecommunication antennas, medical diagnosis and treatment and microwave drying ovens, among others.
Despite the major improvements in estimating exposure, this large case-control study provided no clear evidence for a positive association between cumulative high-frequency EMF exposure and glioma or meningioma risk. However, the number of exposed participants was small: only 10% of the participants were exposed to radiofrequencies and less than 1% were exposed to intermediate frequencies, which limited the statistical power to find clear associations, if they exist.
"Our individualised exposure assessment approach is an important improvement over previous efforts to assess high-frequency EMF exposure risks. Although we did not find a positive association, the fact that we observed indication of an increased risk in the group with most recent radiofrequency exposure deserves further investigation," explains first author Javier Vila. "We also need to investigate possible interactions with other frequencies, and with chemicals," adds Cardis.